Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Fulgent Genetics ( (FLGT) ) is now available.
On May 1, 2026, Fulgent Genetics reported first-quarter 2026 results, posting revenue of $71.1 million, a GAAP net loss of $24.8 million, and a non-GAAP net loss of $11.0 million, while ending the period with $604.7 million in cash and investments, excluding an expected tax refund. Management highlighted solid performance in its laboratory services business and continued clinical progress in its oncology pipeline, including Phase 2 data for FID-007 selected for rapid oral presentation at the 2026 ASCO meeting.
The company reiterated its 2026 revenue outlook of about $350 million, but now projects a non-GAAP loss of roughly $46 million, or $1.59 per share, alongside year-end liquidity of about $636 million assuming delayed tax refunds are received. Fulgent also executed its stock repurchase plan aggressively in the first quarter, spending $40.1 million to buy back about 2.6 million shares, a move that signals confidence in its long-term fundamentals while it absorbs near-term losses and invests in its therapeutic development programs.
The most recent analyst rating on (FLGT) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.
Spark’s Take on FLGT Stock
According to Spark, TipRanks’ AI Analyst, FLGT is a Neutral.
Overall score reflects strong balance-sheet resilience but is held back by weak profitability and sharply negative 2025 cash flow. Technicals are distinctly bearish (price below key moving averages with negative MACD), while guidance points to revenue growth but also a near-term earnings/margin deterioration tied to customer loss and higher spending.
To see Spark’s full report on FLGT stock, click here.
More about Fulgent Genetics
Fulgent Genetics, Inc. is a technology-based precision medicine company operating a laboratory services business and a therapeutic development arm. Its lab segment provides technical testing services and physician-led interpretation, while its drug development unit is advancing nanoencapsulated, targeted cancer therapies such as candidates FID-007 and FID-022, as it seeks to evolve from a diagnostics-focused player into a fully integrated precision medicine platform.
Average Trading Volume: 566,710
Technical Sentiment Signal: Sell
Current Market Cap: $451.9M
For a thorough assessment of FLGT stock, go to TipRanks’ Stock Analysis page.